Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endometrial Safety of Low Dose Estradiol/Dydrogesterone in Postmenopausal Women
NCT00160316Phase 3Completed
- Sponsor
- Solvay
- Start
- Apr 2005
- Primary completion
- Dec 2007
- Modality
- Orthosteric Ligands
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of estradiol and dydrogesterone in postmenopause, sponsored by Solvay. Primary endpoint: Presence of endometrial hyperplasia or a more serious endometrial outcome at 52 weeks. Started Apr 2005; status: completed.
02
Drugs
estradioldydrogesterone
03
Conditions
postmenopause
Beyond the preview
Go deeper on NCT00160316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00160316.